A phase II study of the combination bortezomib (Velcade, PS-341), dexamethasone, and rituximab in patients with Waldenstroms macroglobulinemia
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Results of pooled analysis evaluating the impact of CXCR4 mutations and CXCR4 mutation subtypes on response, PFS and survival after frontline treatment initiation from NCT00250926, NCT01470196 and NCT02400437, released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 10 Mar 2016 According to ClinicalTrials.gov record,time frame for primary end point has been changed from 2 years to 33.2 months.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology